Bluebird bio

December 18, 2018December 18, 2018

LentiGlobin Shows Positive Effects in Severe Sickle Cell Disease Patients, Phase 1/2 Data Reports

News

Bluebird bio presented new positive results from the ongoing Phase 1/2 HGB-206 clinical trial evaluating the effectiveness and safety of investigational gene therapy LentiGlobin in patients with severe sickle cell anemia. ... Read more

June 28, 2018June 28, 2018

Gene Therapy LentiGlobin Continues to Show Good Results, Bluebird Bio Says

News

Bluebird bio reported that its investigational gene therapy LentiGlobin showed promising results for severe sickle cell disease (SCD) patients in a Phase 1 clinical trial. Data from the ongoing HGB-206 Phase ... Read more

January 9, 2018January 9, 2018

Bluebird Bio Presents Positive Early Results of Gene Therapy LentiGlobin for Sickle Cell Disease

News

Bluebird bio announced encouraging interim results from the ongoing Phase 1 clinical trial testing its investigational gene therapy LentiGlobin for patients with severe sickle cell disease (SCD). The results were ... Read more

Pin It on Pinterest